Immunology: Current Research
Open Access

Immune evasion; Tumor immunology; Cancer immunotherapy; Immune checkpoints; Tumor microenvironment; Antigen masking; Immunosuppressive cytokines.

Introduction

Cancer progression is a multifaceted process, and one of the most critical factors in its development is the ability of tumor cells to evade immune surveillance. Immune evasion enables tumors to grow uncontrollably despite the body's immune defenses, and this phenomenon has become a central focus in cancer immunology [1,2]. Under normal conditions, the immune system is capable of detecting and eliminating abnormal cells, including cancer cells, through the recognition of tumor-associated antigens. However, tumors often develop strategies to avoid immune detection or to suppress immune responses, enabling them to persist and spread [3]. Tumor immune evasion mechanisms are diverse and can involve various molecular and cellular changes, such as alterations in antigen presentation, recruitment of immunosuppressive cells, and the secretion of immune-inhibitory cytokines [4]. These mechanisms result in the formation of a tumor microenvironment (TME) that is hostile to immune cell function. Over the past few decades, significant progress has been made in understanding these mechanisms, and research has focused on identifying ways to counteract immune evasion through immunotherapy [5]. Cancer immunotherapy, particularly immune checkpoint inhibitors, has revolutionized treatment for many cancers, but its success is often hindered by the ability of tumors to adapt and escape immune targeting. This review will examine the key immune evasion strategies employed by tumors, their implications for immune responses, and the strategies being developed to overcome them [6]. Additionally, we will explore how the TME influences immune evasion and discuss current therapeutic approaches aimed at enhancing immune system activity against tumors.

Results

Tumors deploy several immune evasion mechanisms to avoid detection and destruction by the immune system. One of the most well-documented mechanisms is the upregulation of immune checkpoint molecules, such as PD-L1, which bind to their receptors on T cells and suppress their activation. This creates a state of immune tolerance, preventing T cells from recognizing and attacking tumor cells. Another mechanism is the alteration of antigen presentation. Tumor cells can downregulate the expression of major histocompatibility complex (MHC) molecules, which are necessary for the presentation of tumor antigens to T cells. This reduces the ability of the immune system to identify and target cancer cells effectively. Additionally, tumors can recruit immunosuppressive cells, such as regulatory T cells (Tregs) and tumor-associated macrophages (TAMs), which secrete cytokines that suppress immune function and promote tumor growth. Tumor cells can also release soluble factors like TGF-β, IL-10, and VEGF, which contribute to immune suppression in the TME. These factors inhibit the function of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, further impairing immune responses. Furthermore, some tumors produce extracellular vesicles that carry immunosuppressive molecules, adding another layer of immune evasion. The interplay between these various immune evasion mechanisms forms a complex network that allows tumors to persist despite immune surveillance. Understanding these mechanisms is crucial for developing strategies to enhance the effectiveness of cancer immunotherapy.

Discussion

Immune evasion is a major obstacle in cancer immunotherapy, and several strategies have been identified to address this challenge. One of the most significant advancements has been the development of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, which block the interaction between PD-1 and PD-L1. These therapies have shown promise in treating cancers such as melanoma, non-small cell lung cancer, and more [7]. However, not all patients respond to immune checkpoint inhibitors, and resistance mechanisms often emerge. The heterogeneity of immune evasion mechanisms across different tumor types and even within the same tumor poses a significant challenge for immunotherapy. One key aspect of immune evasion is the tumor microenvironment (TME), which is often immunosuppressive due to the presence of regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells (MDSCs). These cells create an environment that inhibits the activity of immune effector cells, including cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. In addition to immune checkpoints, recent efforts have focused on targeting the TME itself, including the use of agents that deplete immunosuppressive cells or alter their function [8]. For example, therapies targeting Tregs, TAMs, or MDSCs are being explored in clinical trials. Furthermore, the combination of immune checkpoint inhibitors with other therapeutic strategies, such as targeted therapies or radiation, may enhance immune responses and overcome resistance. Another promising approach is the use of oncolytic viruses, which selectively infect and kill tumor cells while stimulating an immune response. While significant progress has been made in cancer immunotherapy, overcoming immune evasion remains a complex challenge that requires a multifaceted approach to enhance treatment efficacy and patient outcomes.

Conclusion

Immune evasion is a critical factor in cancer progression and resistance to immunotherapy. Tumors have evolved a wide range of mechanisms to escape immune detection, including immune checkpoint activation, antigen loss, recruitment of suppressive immune cells, and the secretion of immunosuppressive cytokines. These mechanisms create a hostile tumor microenvironment that impairs the function of immune effector cells and limits the effectiveness of cancer immunotherapies. However, advancements in our understanding of these immune evasion strategies have led to the development of innovative therapeutic approaches. Immune checkpoint inhibitors have revolutionized cancer treatment, but their effectiveness is limited by the complex and heterogeneous nature of immune evasion. Additionally, personalized approaches based on the specific immune evasion mechanisms of individual tumors may provide more effective treatments. Overcoming immune evasion will require continued research into the intricate interactions between tumor cells and the immune system, and the development of novel strategies to enhance immune responses against cancer. Ultimately, a better understanding of immune evasion mechanisms will pave the way for more effective immunotherapies and improved outcomes for cancer patients.

Acknowledgment

None

Conflict of Interest

None

References

1. Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.

Indexed at, Google Scholar, Crossref

2. Zhao W, Shan B, He D, Cheng Y, Li B, et al. (2019) Recent Progress in Characterizing Long Noncoding RNAs in Cancer Drug Resistance. J Cancer 10: 693-702.

Indexed at, Google Scholar, Crossref

3. Yang E, Wang X, Gong Z, Yu M, Wu H, et al. (2020) Exosome-mediated metabolic reprogramming: The emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduct Target Ther 5: 242.

Indexed at, Google Scholar, Crossref

4. Ragusa M, Barbagallo C, Cirnigliaro M, Battaglia R, Brex D, et al. (2017) Asymmetric RNA Distribution among Cells and Their Secreted Exosomes: Biomedical Meaning and Considerations on Diagnostic Applications. Front Mol Biosci 4: 66-80.

Indexed at, Google Scholar, Crossref

5. Wang S, Wang J, Wei W, Ma G (2019) Exosomes: The Indispensable Messenger in Tumor Pathogenesis and the Rising Star in Antitumor Applications. Adv Biosyst 3: e1900008.

Indexed at, Google Scholar, Crossref

6. Darband SG, Mirza M, Kaviani M, Mihanfar A, Sadighparvar S, et al. (2018) Exosomes: Natural nanoparticles as bio shuttles for RNAi delivery. J Control Release 289: 158-170.

Indexed at, Google Scholar, Crossref

7. Chen DF, Hu L, Yi P, Liu WW, Fang DC, et al. (2007) Hpylori are associated with chronic cholecystitis. World J Gastroenterol 13: 1119-1122.

Indexed at, Google Scholar, Crossref

8. Grace PY, Chiang D, Song SJ, Hoyte EG, Huang J, et al. (2009) Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin immunol 131: 240-253.

Indexed at, Google Scholar, Crossref